• Superoxide Dismutase (SOD) Activity Assay Kit: Protocol and

  2026-07-17

  The Superoxide Dismutase (SOD) Activity Assay Kit provides a sensitive, colorimetric method for quantifying SOD enzyme activity in biological fluids, supporting oxidative stress and antioxidative enzyme studies. It is well-suited for research applications requiring precise measurement of SOD but is not intended for clinical diagnostics or medical decision-making.

• HRP Rabbit Anti-Goat IgG (H+L) Antibody: Enhanced Immunodete

  2026-07-17

  Explore how the HRP Rabbit Anti-Goat IgG (H+L) Antibody delivers robust, high-sensitivity detection in advanced immunodetection workflows. This article uniquely bridges assay optimization with cutting-edge environmental toxicology, offering practical insights for research on micro- and nanoplastics-induced pulmonary fibrosis.

• Optimizing Cell-Based Assays with Cy5 Goat Anti-Mouse IgG (H

  2026-07-16

  This article addresses key laboratory challenges in cell viability and immunofluorescence workflows, focusing on the scientific and practical advantages of Cy5 Goat Anti-Mouse IgG (H+L) Antibody (SKU K1210). By examining real-world scenarios, we demonstrate how this Cy5-conjugated secondary antibody enables reproducible, high-sensitivity detection and robust data reliability for biomedical researchers.

• Thioguanine: Precision Antitumor and Antiviral Applications

  2026-07-16

  Explore how Thioguanine (6-thioguanine) enables precision inhibition of cancer and viral replication. This in-depth analysis uncovers unique mechanistic and assay-guided insights for researchers seeking advanced applications beyond standard workflows.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-15

  This study demonstrates that suppressing TRIB3 expression in clear cell renal cell carcinoma (ccRCC) cells enhances their sensitivity to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. These findings offer mechanistic insight into overcoming sunitinib resistance and suggest new avenues for ccRCC therapeutic strategies.

• Hydrocortisone in Glucocorticoid Hormone Research Models

  2026-07-15

  Hydrocortisone (CAS 50-23-7) empowers advanced inflammation and stress response research, extending from barrier function assays to neuroprotection in disease models. With APExBIO’s high-purity formulation, researchers achieve reproducible results and streamlined troubleshooting in both cellular and animal contexts.

• Hydrocortisone (B1951): Protocol Guidance for Research Workf

  2026-07-14

  Hydrocortisone (SKU B1951) addresses the need for a well-characterized glucocorticoid hormone in inflammation model research, stress response mechanism studies, and neuroprotection workflows. It is best used where precise modulation of glucocorticoid receptor signaling and reproducible compound handling are critical. Hydrocortisone is not suitable for direct clinical application or for protocols requiring aqueous solubility.

• WTAP-Driven Glutaminase Splicing Suppresses Ferroptosis in H

  2026-07-14

  The reference study elucidates how EGFR-driven phosphorylation of WTAP promotes alternative splicing of the glutaminase gene in hepatocellular carcinoma (HCC), favoring the GAC isoform and conferring resistance to ferroptosis. These findings highlight a unique epigenetic mechanism linking oncogenic signaling, metabolic reprogramming, and tumor survival, opening avenues for new therapeutic strategies targeting m6A-dependent splicing events.

• Dronedarone (Multaq): Experimental Excellence in AF Research

  2026-07-13

  Dronedarone (Multaq) from APExBIO elevates atrial fibrillation and flutter research with its high purity, robust solubility, and proven pharmacological profile. This guide delivers actionable protocols and troubleshooting strategies to maximize reproducibility and data quality in advanced cardiac arrhythmia studies.

• Adipose-Neural Axis and NPY/Y1R Signaling in Cardiac Arrhyth

  2026-07-13

  Fan et al. (2024) elucidate how epicardial adipose tissue (EAT) interacts with the sympathetic nervous system to drive cardiac arrhythmias via leptin–NPY/Y1R signaling. Their stem cell-based coculture model pinpoints molecular intervention targets, providing new mechanistic understanding and potential therapeutic avenues for arrhythmia management.

• Distinct Roles of ERK5 and ERK1/2 in Vitamin D3-Induced AML

  2026-07-12

  This study reveals that the ERK5 MAPK pathway has a unique and major role in 1α,25-dihydroxyvitamin D3-induced terminal differentiation of myeloid leukemia cells, distinct from ERK1/2 signaling. The findings clarify how selective inhibition of these kinases alters differentiation and cell cycle progression, informing the design of targeted therapies and research protocols.

• Decoding Mucosal Damage: DSS Models and GPR35-KLF5 Repair Ci

  2026-07-10

  Explore the mechanistic foundation and translational strategy for modeling and repairing colonic epithelial damage using Dextran sulfate sodium salt (MW 35000-45000). This article bridges emerging insights into GPR35-KLF5 metabolic gatekeeping with actionable guidance for designing robust ulcerative colitis studies, highlighting APExBIO’s DSS as a gold-standard tool for preclinical innovation.

• iPSC-Based Prescreening for Ultrarare Disease Clinical Trial

  2026-07-09

  This study presents a personalized induced pluripotent stem cell (iPSC)-based platform to prescreen drug efficacy for patients with ultrarare diseases, addressing the challenge of unpredictable responses in clinical trial enrollment. The approach demonstrates improved safety and efficacy validation, guiding individualized treatment decisions for previously uncharacterized pathogenic mutations.

• CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition

  2026-07-09

  CUDC-907 provides researchers with a validated tool for simultaneous inhibition of PI3K/AKT and HDAC pathways in established cancer cell models. It is specifically intended for controlled in vitro studies focused on cell signaling, cell cycle arrest, and apoptosis. CUDC-907 should not be used for clinical, diagnostic, or therapeutic applications.

• Surrogate BBB Model with Lysosomal Trapping Correction Advan

  2026-07-08

  The referenced study introduces a high-throughput in vitro blood-brain barrier (BBB) model combining LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction to predict CNS drug permeability. This approach improves mechanistic resolution and predictive accuracy, streamlining early-stage screening for brain-penetrant therapeutics.

11884 records 1/793 page Next 12345 下5页 Last page